Quantum Genomics Eo Stock Net Income

2QG Stock  EUR 0.07  0.00  0.00%   
QUANTUM GENOMICS EO technical analysis gives you tools to exploit past data patterns in attempt to determine a pattern that determines the direction of the company's future prices.
QUANTUM GENOMICS's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing QUANTUM GENOMICS's valuation are provided below:
Gross Profit
-1.1 M
Market Capitalization
4.5 M
Enterprise Value Revenue
11.062
Revenue
10
Earnings Share
(0.80)
QUANTUM GENOMICS EO does not now have any fundamental measures for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Understanding that QUANTUM GENOMICS's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether QUANTUM GENOMICS represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, QUANTUM GENOMICS's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

QUANTUM GENOMICS 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to QUANTUM GENOMICS's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of QUANTUM GENOMICS.
0.00
11/08/2025
No Change 0.00  0.0 
In 3 months and 1 day
02/06/2026
0.00
If you would invest  0.00  in QUANTUM GENOMICS on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding QUANTUM GENOMICS EO or generate 0.0% return on investment in QUANTUM GENOMICS over 90 days. QUANTUM GENOMICS is related to or competes with Charter Communications, Citic Telecom, Gamma Communications, Entravision Communications, and Bank of America. Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases More

QUANTUM GENOMICS Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure QUANTUM GENOMICS's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess QUANTUM GENOMICS EO upside and downside potential and time the market with a certain degree of confidence.

QUANTUM GENOMICS Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for QUANTUM GENOMICS's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as QUANTUM GENOMICS's standard deviation. In reality, there are many statistical measures that can use QUANTUM GENOMICS historical prices to predict the future QUANTUM GENOMICS's volatility.
Hype
Prediction
LowEstimatedHigh
0.060.070.07
Details
Intrinsic
Valuation
LowRealHigh
0.060.060.07
Details
Naive
Forecast
LowNextHigh
0.070.070.07
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.070.070.07
Details

QUANTUM GENOMICS Backtested Returns

We have found three technical indicators for QUANTUM GENOMICS, which you can use to evaluate the volatility of the company. The company owns a Beta (Systematic Risk) of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and QUANTUM GENOMICS are completely uncorrelated.

Auto-correlation

    
  0.00  

No correlation between past and present

QUANTUM GENOMICS EO has no correlation between past and present. Overlapping area represents the amount of predictability between QUANTUM GENOMICS time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of QUANTUM GENOMICS price movement. The serial correlation of 0.0 indicates that just 0.0% of current QUANTUM GENOMICS price fluctuation can be explain by its past prices.
Correlation Coefficient0.0
Spearman Rank Test1.0
Residual Average0.0
Price Variance0.0
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, QUANTUM GENOMICS EO reported net income of (11.54 Million). This is 103.38% lower than that of the Biotechnology sector and 116.47% lower than that of the Health Care industry. The net income for all Germany stocks is 102.02% higher than that of the company.

QUANTUM Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses QUANTUM GENOMICS's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of QUANTUM GENOMICS could also be used in its relative valuation, which is a method of valuing QUANTUM GENOMICS by comparing valuation metrics of similar companies.
QUANTUM GENOMICS is currently under evaluation in net income category among its peers.

QUANTUM Fundamentals

About QUANTUM GENOMICS Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze QUANTUM GENOMICS EO's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of QUANTUM GENOMICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of QUANTUM GENOMICS EO based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in QUANTUM Stock

QUANTUM GENOMICS financial ratios help investors to determine whether QUANTUM Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in QUANTUM with respect to the benefits of owning QUANTUM GENOMICS security.